Yasser Ged, MD

In this final segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss the evolving landscape of renal cell carcinoma with a focus on investigational triplet strategies such as those being evaluated in the LITESPARK-012 trial.

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss the clinical implications of recently presented phase 3 data from the LITESPARK-011 trial in renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how first-line treatment selection influences sequencing strategies in renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack and Dr. Sundhar Ramalingam discuss the practical considerations of dose management for IO plus TKI combinations in renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across different IMDC risk groups.

In this segment, Dr. Elizabeth Plimack and Dr. Sundhar Ramalingam discuss the relationship between clinical trial outcomes and real-world experience in the management of renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on the challenges of comparing first-line treatment regimens in renal cell carcinoma across different clinical trials.

In this segment, Dr. Elizabeth Plimack and Dr. Sundhar Ramalingam discuss how the quality of response achieved in the first-line setting influences subsequent treatment strategies in renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on the concept of durable responses and the potential long-term survival tail observed with first-line immunotherapy-based regimens in renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged examine how clinicians interpret progression-free survival and overall survival when evaluating first-line treatment options in renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack and Dr. Sundhar Ramalingam discuss how clinicians interpret long-term outcomes from first-line clinical trials in renal cell carcinoma, including studies such as CLEAR.

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians balance key efficacy endpoints when selecting first-line therapy for renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged focus on the management of non–clear cell renal cell carcinoma, a group of histologies that has historically been underrepresented in large phase 3 trials.

In this segment, Dr. Elizabeth Plimack invites both Dr. Sundhar Ramalingam and Dr. Yasser Ged to discuss the growing role of combination therapies in the first-line treatment of renal cell carcinoma.

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged explore how clinical trials in renal cell carcinoma have evolved, particularly in the first-line setting.

Dr. Elizabeth Plimack and Dr. Sundhar Ramalingam discuss the evolving treatment landscape of renal cell carcinoma, emphasizing that first-line therapy selection is a critical, strategic decision that significantly influences patient outcomes, disease control, and subsequent treatment options.